Over the past ten years there has been a rapid increase in new biological (targeted) anti-cancer therapies. This brings challenges for nurses to understand how such drugs work, how they are administered and the implications for patients in terms of potential side effects. Bevacizumab (Avastin^®▼) is a monoclonal antibody that targets vascular endothelial growth factor. It is licensed for use in several cancers to treat patients with advanced or metastatic disease including breast, colorectal, renal, non-small cell lung and ovarian. However, there are regional variations in funding arrangements, which nurses should be aware of.